Percutaneous Coronary Intervention - Adverse events with drug-eluting stents

While drug eluting stents have been successful in reducing the rate of restenosis following percutaneous coronary intervention, there have been safety scares over a new problem: “in-stent thrombosis”. Opinion leaders are divided over the gravity of this problem, but positive safety data are required to restore physician confidence in drug eluting stents.

Hypertension Therapy and Market Report

MARKET RESEARCH OF DRUGS USED IN ATOPIC RHINITIS IN INDIA

The present paper enumerates the pathophysiological conditions of atopic rhinitis and emphasis was made to gather the information about the drugs and to reveal the present status in the market. During the course of present survey of the drugs used in atopic rhinitis, it was found that cetrizine and levocetrizine (antihistamines-II generation), are widely used in Indore locality.

Pharmaceutical  Market Trends in 2007

“In 2007, the market will still be absorbing changes that have defined a new economic reality, one in which growth is shifting from mature markets to emerging ones; new product adoption is not keeping pace with the loss of patent protection by established products; specialty and niche products are playing a larger role; and regulators, payers and consumers are more carefully weighing the risk/benefit factors of pharmaceuticals.”, says Murray Aitken, Senior VP, Corporate Strategy at IMS. 

Albania - Pharmaceuticals and Health Care Technology Assessment

Albania has embarked upon major health sector reforms, but it is greatly hampered by political instability and a struggling economy. Nevertheless, the population enjoys reasonable health according to key indicators such as life expectancy, a situation that is particularly impressive in a context of widespread poverty and very low spending on health care.

The Future of the Life Sciences Industries: Strategies for Success in 2015

Life Sciences Execs See Dramatic Change in the Coming Decade

Businesses engaged in the life sciences are poised to undergo dramatic change in the next decade, according to a unique survey of top executives in the field undertaken by Deloitte Touche Tohmatsu (DTT) member firms. Full 36 page report is available for download at Repository of the Farmavita.Net.

Pharma Market in Spain – a work in progress

Within Europe, the overall Spanish pharmaceutical market is the 5th largest with a value of US$ 11.2 billion according to IMS. At the same time, its generic market totalled only around US$800m, equivalent to only 7.1% of the overall value, making it one of the smallest generic markets.

Consequences, opportunities and challenges of modern biotechnology for Europe

The Biotechnology for Europe Study

Modern biotechnology is one of the key enabling technologies of the 21st century with a potentially wide range of applications in many sectors, including health, agriculture and industrial processes.

The Complete 149 pages Study is available  for download at Farmavita.Net 

Central and Eastern Europe Pharmaceutical Industry - An Overview

The Czech Republic, Estonia, Hungary, Latvia, Lithuania, Poland, Slovak Republic and Slovenia are the new Central and Eastern European (CEE) countries. The pharmaceutical market in these countries has been relatively small when compared to the Western European countries. In 2006, the pharmaceutical market in CEE countries has been estimated to be $9.20 billion. It has grown rapidly over the past few years and is likely to reach around $14.00 billion by 2010.